Sat, 30 Jun 2018 15:10:57 GMT
Novartis chairman claims Alcon worth $20-$30B
The chairman of the Swiss drugmaker Novartis anticipates Alcon to be valued between $20B and $30B after the new ophthalmic devices unit is rolled out to shareholders in the following year.